

CLINICAL TRIAL PROTOCOL

Open Access

# Protocol TOP-Study (tacrolimus organ perfusion): a prospective randomized multicenter trial to reduce ischemia reperfusion injury in transplantation of marginal liver grafts with an *ex vivo* tacrolimus perfusion

Sebastian Pratschke<sup>1</sup>, Michael Eder<sup>1</sup>, Michael Heise<sup>2</sup>, Silvio Nadalin<sup>3</sup>, Andreas Pascher<sup>4</sup>, Peter Schemmer<sup>5</sup>, Marcus N Scherer<sup>6</sup>, Frank Ulrich<sup>7</sup>, Heiner Wolters<sup>8</sup>, Karl-Walter Jauch<sup>1</sup>, Dirk Wöhling<sup>9</sup> and Martin K Angele<sup>1\*</sup>

## Abstract

**Background:** Critical organ shortage results in the utilization of extended donor criteria (EDC) liver grafts. These marginal liver grafts are prone to increased ischemia reperfusion injury (IRI) which may contribute to deteriorated graft function and survival. Experimental data have shown that the calcineurin inhibitor tacrolimus exerts protective effects on hepatic IRI when applied intravenously or directly as a hepatic rinse. Therefore, the aim of the present study is to examine the effects of an *ex vivo* tacrolimus perfusion on IRI in transplantation of EDC liver grafts.

**Methods/Design:** The TOP-Study (tacrolimus organ perfusion) is a randomized multicenter trial comparing the *ex vivo* tacrolimus perfusion of marginal liver grafts with placebo. We hypothesize that a tacrolimus rinse reduces IRI, potentially improving organ survival following transplantation of EDC livers. The study includes livers with two or more EDC, according to Eurotransplant International Foundation's definition of EDC livers. Prior to implantation, livers randomized to the treatment group are rinsed with tacrolimus at a concentration of 20 ng/ml in 1000 ml Custodiol solution and in the placebo group with Custodiol alone. The primary endpoint is the maximum serum alanine transaminase (ALT) level within the first 48 hours after surgery; however, the study design also includes a 1-year observation period following transplantation. The TOP-Study is an investigator-initiated trial sponsored by the University of Munich Hospital. Seven other German transplant centers are participating (Berlin, Frankfurt, Heidelberg, Mainz, Münster, Regensburg, Tübingen) and aim to include a total of 86 patients.

**Discussion:** Tacrolimus organ perfusion represents a promising strategy to reduce hepatic IRI following the transplantation of marginal liver grafts. This treatment may help to improve the function of EDC grafts and therefore safely expand the donor pool in light of critical organ shortage.

**Trial register:** EudraCT number: 2010-021333-31, ClinicalTrials.gov identifier: NCT01564095

**Keywords:** Liver transplantation, Organ shortage, Extended donor criteria, Marginal grafts, Tacrolimus, Organ rinse, Graft function, Graft survival

\* Correspondence: Martin.Angele@med.uni-muenchen.de

<sup>1</sup>Department of Surgery, University of Munich Hospital, Campus Grosshadern, Ludwig-Maximilians-University, Marchioninistrasse 15, 81377 Munich, Germany

Full list of author information is available at the end of the article

## Introduction

Organ shortage represents a critical problem in transplantation medicine. In 2010, 1192 liver transplantations were performed in Germany as opposed to 1846 new entries on the waiting list (German Organ Transplantation Foundation (Deutsche Stiftung Organtransplantation, DSO), Annual Report, 2010). As a consequence of this discrepancy, there is a noticeable trend towards the utilization of extended donor criteria (EDC) grafts. Data provided by the Eurotransplant International Foundation indicate that the proportion of liver grafts exhibiting one or more EDC increased from 29% in 1997 to 73% in 2010 (Axel Rahmel, Medical Director, Eurotransplant, personal communication). The proportion of grafts with two or more EDC increased from 4% up to 28% over the same time period.

Ischemia reperfusion injury (IRI) is a complex inflammatory, allogene-independent process commonly seen following graft transplantation; however, it is particularly pronounced in marginal organs [1-3], and may contribute to poor graft function and reduced survival in these recipients [4,5]. During ischemia and reperfusion, proinflammatory cytokines such as IL-6 or TNF- $\alpha$  are released into the systemic circulation by Kupffer cells and migrating neutrophils [6]. These molecules induce a complex inflammatory cascade and trigger the generation of reactive oxygen species (ROS) thereby affecting the redox status of the cell [7]. In turn, increased intracellular levels of oxidized glutathione contribute to impairment of the liver's antioxidative defense system [8]. In addition to sinusoidal congestion caused by endothelial sticking of migrating neutrophils, an imbalance between vasoconstrictive (endothelin-1) [9] and vasodilatory substances (NO) [10] may directly disturb the hepatic microcirculation. This is considered to be a central pathomechanism for organ dysfunction and primary nonfunction [9,10], especially in marginal

liver grafts [11,12]. Besides poor graft quality, the recipients' health status (model for end-stage liver disease (MELD) score) may also influence the outcome after liver transplantation [13]. The combination of extended criteria donors and poor recipient condition may be responsible for a reduction of graft survival following liver transplantation. In 2011, the 5-year graft survival rate in Germany was 52.6% compared to the international mean of 66.2% (data provided by DSO, Collaborative Transplant Study (CTS)).

Therefore, strategies must be developed to improve the function and survival of EDC organs. Several experimental models have shown that tacrolimus preconditioning before liver transplantation has protective effects (Table 1). The authors have recently demonstrated that an *ex vivo* tacrolimus flush reduces IRI in a model of experimental liver transplantation in rats [14]. Based on these experimental findings, a study protocol of a single *ex vivo* tacrolimus rinse prior to reperfusion in marginal livers was developed (Trial register: EudraCT number: 2010-021333-31, ClinicalTrials.gov identifier: NCT 01564095). The aim of the TOP-Study (tacrolimus organ perfusion) is to reduce hepatic IRI and improve long-term organ survival following transplantation of marginal livers.

## Hypothesis and endpoints

The hypothesis of the study is that a single *ex vivo* tacrolimus perfusion prior to reperfusion reduces IRI and improves long-term graft survival. The primary endpoint is the maximum alanine transaminase (ALT) level within the first 48 hours following liver transplantation. Secondary endpoints are ALT and aspartate transaminase (AST) levels, graft function (prothrombin time, bilirubin), and creatinine on days 1, 2, 4 and 7. In addition, the study documents graft and patient survival, histologically confirmed rejection, as well as ischemic-type biliary lesions (ITBL).

**Table 1 Tacrolimus and ischemia reperfusion injury experimental animal studies**

Author	Cold vs warm ischemia	Ischemic time	Species	TAC-application: Systemic vs organ rinse	End points	P
Sakr et al., 1991 [15]	Warm	45 minutes	Rat	Systemic	Survival, aminotransferases, LDH	<0.05
Kawano et al., 1995 [16]	Warm	60 minutes	Rat	Systemic	Microcirculation, aminotransferases	<0.05
Kawano et al., 1996 [17]	Cold	80 minutes	Rat	Systemic	Lipid peroxidation, aminotransferases	<0.05
Garcia-Criado et al., 1997 [18]	Warm	90 minutes	Rat	Systemic	Survival ROS, cytokines, aminotransferases, neutrophil infiltration	<0.01 <0.05
Takeichi et al., 2009 [19]	Warm	50 minutes	Rat	Systemic	Aminotransferases, neutrophil activation	<0.05
Huser et al., 2009 [20]	Cold	120 minutes	Rat	Systemic	Aminotransferases, histology	0.001
Pratschke et al., 2012 [14]	Cold	24 hours	Rat	Organ rinse	Aminotransferases, glutathione metabolism	<0.05

LDH, lactate dehydrogenase; ROS, reactive oxygen species; TAC, tacrolimus.

## Methods

The TOP-Study is an investigator-initiated, prospective, randomized trial comparing the *ex vivo* perfusion of marginal livers with tacrolimus to placebo prior to transplantation. The main inclusion criterion is the presence of two or more EDC. IRI is assessed by serum ALT and AST levels over a period of 7 days. Following this period, organ and patient survival, bile duct complications, rejections and organ function are monitored for 1 year. The TOP-Study is sponsored by the University of Munich Hospital with financial support provided by a grant from Astellas Pharma GmbH, München, Germany. Research and organizational support is provided by the contract research organisation (CRO) DABIO Gesellschaft für Auftragsforschung mbH, Höhenkirchen, Germany.

## Inclusion and exclusion criteria

The study includes patients undergoing liver transplantation in the participating centers who meet the following criteria: chronic terminal liver failure, over 18 years of age, first liver transplantation, and informed, signed consent by the recipient. Donor organs exhibiting two or more EDC according to the Eurotransplant Manual for extended criteria liver donors (Table 2) are included [21].

Patients receiving split liver and multiorgan transplantations are excluded as well as those undergoing retransplantation, high urgency transplantation or pediatric transplantation. In addition, recipients with extrahepatic malignant diseases, and organs from donors with hepatitis B or C infection, are excluded.

## Perfusion procedure

Livers are perfused with 1000 ml of the rinse solution from a height of 100 cm without additional pressure using polyvinylchloride (PVC)-free infusion systems with a 12 gauge cannula. The portal vein and the common

**Table 2 Extended donor criteria (EDC)**

Criteria	
Donor age	>65 years
Macrovesicular steatosis	>40% (macroscopy or biopsy)
BMI	>30
Sodium	>165 mmol/l
ICU stay and ventilation	>7 days
Cold ischemia time	>13 hours
AST	>99 u/l
ALT	>105 u/l
Bilirubin	>3 mg/dl (>51 µmol/l)
Application of epinephrine	

Criteria according to the Eurotransplant Manual for EDC in liver grafts [21]. BMI, body mass index; EDC, extended donor criteria; ICU, intensive care unit; ALT, alanine transaminase; AST, aspartate transaminase.

hepatic artery are flushed sequentially, with 500 ml each. In the test arm, tacrolimus is added to 1000 ml Custodiol histidine-tryptophan-ketoglutarate (HTK) solution at a concentration of 20 ng/ml. A total of 20 µg tacrolimus is applied. In the placebo group livers are perfused with 1000 ml Custodiol. The perfusion procedure is performed at the end of the back-table preparation at least 1 hour before reperfusion. The duration of the perfusion does not exceed 15 minutes (Figure 1). Prior to reperfusion livers are flushed *in situ* with 500 ml of the recipients' blood.

## Liver transplantation and postoperative immunosuppressant regimen


Liver transplantation is performed according to the standard clinical practice at each center. Immunosuppression during the first 7 postoperative days is tacrolimus-based. Thereafter, a tacrolimus-based immunosuppressive regimen is suggested but not mandatory. Additional immunosuppression, that is, corticoids, is administered at the discretion of the treating clinician.


## Follow-up

The present trial includes a 7-day interventional study regulated by the German Pharmaceuticals Act (Arzneimittelgesetz, AMG) and a non-interventional study (NIS) over 1 year (Figure 2). During the entire study period, the monitoring of safety and data is performed according to Good Clinical Practice (GCP) guidelines. Data management and CRO duties are performed by the DABIO Gesellschaft für Auftragsforschung mbH, Höhenkirchen, Germany.

## Study visits

To characterize IRI and graft function serum ALT/AST, prothrombin ratio and bilirubin are measured on postoperative days 1, 2, 4, 7, as well as 6 and 12 months following liver transplantation (Figure 2). Moreover, graft and patient survival, bile duct complications and histologically confirmed rejections are assessed.





**Figure 2** Study visits TOP-Study (tacrolimus organ perfusion).

### Sample size, statistical analysis, randomization

The primary endpoint of the study is the maximum serum ALT level within 48 hours following liver transplantation, which reflects the degree of acute hepatocellular injury. Non-parametric analysis using Wilcoxon rank-sum test is performed to compare the maximum ALT levels in grafts treated with tacrolimus versus placebo. Based on a previous study using non-marginal healthy grafts, an effect size of approximately 0.5 was calculated [22]. In experimental studies, therapies for the treatment of IRI were more effective in steatotic livers [23,24]. Since recipients of marginal organs are incorporated in the present study, the predicted improvement in postoperative ALT levels should be higher than in non-marginal grafts. Thus, an effect size of 0.7 was considered appropriate for the sample size calculation. The power of the test is 80% at a significance level of 0.05. Therefore, sample size estimation (nQuery Advisor 6.1, Statistical Solutions, Saugus, MA, USA) for two unpaired samples using the Wilcoxon rank-sum test with an expected dropout rate of 15% results in an estimated sample size of 86 (43 tacrolimus vs 43 placebo).

To homogenize the patient collective only marginal organs with two or more EDC are included. Nonetheless, all EDC may affect the primary endpoint. Since documentation of EDC is required for patient inclusion, those parameters will be analyzed as potential confounders. Moreover, recipient age will also be registered.

### Participating centers

The Departments of Surgery of the following German university hospitals are participating in this trial: Charité Campus Virchow-Klinikum, Berlin; Johann Wolfgang Goethe-University, Frankfurt am Main; Johannes Gutenberg University, Mainz; Westphalian Wilhelms-University, Münster; Ruprecht-Karls-University, Heidelberg; University of Regensburg; Eberhard Karls University, Tübingen; and Campus Grosshadern, Ludwig-Maximilians-University, Munich.

### Ethics and safety

Protocol version 2.1 has been approved by the local ethic committees of the ethics committee of the university of

Munich. The study complies with the Declaration of Helsinki and GCP guidelines. Informed consent is obtained from each patient in written form prior to randomization. The patient is informed about the nature, duration and possible consequences of the trial by an investigator specifically registered for this trial.

### Current status (October 2012)

Study permission by the Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM) was received on 29 July 2011 and ethics committee approval on 23 August 2011. Version 2.1 of the protocol is active. To date (October 2012), seven centers (Berlin, Frankfurt, Heidelberg, Mainz, Munich, Regensburg and Tübingen) have been initiated and 17 patients have been recruited for the study. Estimated closure for recruitment for the study will be 31 December 2013. One year thereafter the study will be closed. Data calculation will require 6 months. A finalized report of the study is expected for July 2015.

### Discussion

Organ shortage and the consecutive transplantation of EDC grafts remain an unsolved problem in organ transplantation. Marginal organs are increasingly accepted, which is associated with increased acute IRI [4,23] and diminished graft survival [5,25,26]. An increased susceptibility of marginal organs to the pathomechanisms of IRI is discussed as a potential cause for the impaired outcome of these grafts [2,3]. Thus, clinically relevant strategies must be developed to prevent IRI in marginal organs.

Several experimental studies have demonstrated protective effects of tacrolimus on IRI following liver transplantation [14,17,20]. Despite their promising results, these models were based on systemic donor preconditioning, which is logistically difficult to incorporate into clinical practice due to the existing organ allocation practice in the Eurotransplant zone.

An *ex vivo* tacrolimus treatment may represent a solution to this problem. Recent experimental data indicates a protective effect of an *ex vivo* tacrolimus rinse in a model of experimental liver transplantation in rats [14]. Preservation of intracellular glutathione levels was suggested as a potential mechanism in this study. The calcineurin inhibitor tacrolimus acts through a blockade of the intracellular calcineurin-calmodulin complex. This blockade inhibits the calcium-dependent phosphorylation of the nuclear factor of activated T cells (NFAT). As a consequence, IL-2, which is normally involved in the activation of CD4+ and CD8+ T cells, and the IL-2 receptor are downregulated. Thus, the inactivation of T cells is regarded as the central mechanism in the immunosuppressant properties of tacrolimus [27,28].

In addition, tacrolimus might attenuate allogeneic independent hepatic IRI, which is characterized by the release of a complex cascade of cytokines including IL-6 and TNF- $\alpha$ , the generation of ROS, the accumulation and transmigration of different cell types (that is, lymphocytes, neutrophils, platelets), as well as alterations of the microcirculation potentially causing graft dysfunction or even non-function [6]. In this respect, T cells have been shown to be critically involved in the induction of IRI of the liver [29-32]. A rapid recruitment of CD4+ T cells in hepatic sinusoids as early as 30 minutes after reperfusion is followed by their migration through the endothelial barrier to injured hepatic tissue [30]. Although CD4+ T cells themselves are not cytotoxic, they release a panel of cytokines, chemokines and adhesion molecules which are potentially harmful to the organ. Moreover, CD4+ T cells interact with platelets and Kupffer cells which further aggravate IRI [33]. However, it has yet to be determined whether tacrolimus affects IRI after liver transplantation via CD4+ T cells.

Neutrophils are also actively involved in hepatic IRI. The accumulation of neutrophils congests hepatic sinusoids and leads to the release of proinflammatory cytokines (that is, TNF- $\alpha$  and IL-6), as well as ROS [34]. Adhesion molecules such as P-selectin and ICAM-1 are involved in the process of neutrophil recruitment [35]. The application of tacrolimus decreases the expression of these adhesion molecules, thereby attenuating neutrophil recruitment [36,37]. In addition, direct suppressive effects of tacrolimus on the activation of Kupffer cells, which also release proinflammatory cytokines have been demonstrated *in vitro* [38]. This anti-inflammatory effect of tacrolimus was also evident in human liver biopsies after the transplantation of organs rinsed with tacrolimus [39].

With respect to the microcirculation, direct effects of tacrolimus on the expression of vasoconstrictive substances (endothelin-1) in endothelial cells have been shown, which might further improve hepatic microcirculation [40]. Increased levels of ROS are known to be involved in the pathogenesis of IRI. The application of tacrolimus *in vivo* is associated with a reduction of ROS [18]. Recently, a rat model of liver transplantation demonstrated that tacrolimus increases glutathione metabolism, which in turn may protect organ function by reducing ROS toxicity [14]. Tacrolimus has also been found to exert anti-apoptotic effects by preventing Fas-induced apoptosis in human hepatocytes *in vitro* [41], as well as in an *in vivo* model of IRI in rats [42]. A decrease in liver apoptosis may contribute to persisting protection of cellular integrity. In summary, several potentially synergistic mechanisms for the protective effects of tacrolimus in the setting of ischemia-reperfusion injury have been proposed.

Preliminary clinical data have shown beneficial results of tacrolimus preconditioning in human liver transplantation (Table 3). In addition, the tacrolimus rinse procedure has been tested clinically in a phase I trial (Table 3). In a previous trial, Peter *et al.* demonstrated a significant reduction of aminotransferase levels following the transplantation of normal livers rinsed with 20 ng/ml tacrolimus [22]. Although the results of this trial were promising, the clinical impact was limited by the small number of patients included (n = 20). In a similar clinical study, Kristo *et al.* recently failed to show a reduction in ALT levels on day 6 after transplantation [39]. However, the study population was relatively small, and, as most patients received healthy organs, the results cannot be directly compared to a study of marginal grafts. Postoperative aminotransferase levels in the Kristo *et al.* study were generally quite low, with serum ALT levels in the control group reaching almost normal levels 6 days after transplantation [39]. Nevertheless, the authors showed an impressive reduction in precursors of proinflammatory enzymes following tacrolimus rinse [39].

In the TOP-Study, livers are treated with a single *ex vivo* tacrolimus rinse prior to implantation, with the aim of reducing graft damage and secondarily improving the long-term course of EDC grafts. The maximum ALT level within the first 48 hours following liver transplantation was chosen as a clinical marker of hepatic injury and used to estimate the degree of IRI. Aminotransferases have been shown to be an appropriate marker of hepatic IRI in a number of studies. Puhl *et al.* demonstrated an inverse correlation between microcirculation, a key factor in the development of IRI, and serum ALT/AST levels in human liver transplantation [43]. Moreover, EDC organs, which are associated with increased levels of IRI, display significantly elevated ALT/AST levels [4]. In addition to assessing acute IRI, the TOP-Study assesses graft survival during a 1-year follow-up period. Although the impact of acute graft injury on long-term survival is discussed controversially in the literature, there is strong evidence that IRI correlates significantly with long-term graft survival [44].

The tacrolimus concentration of 20 ng/ml was chosen in the present trial based on safety data from previous

**Table 3 Clinical studies of tacrolimus rinse in liver transplantation**

Author	Number of patients	Result		P
		Tacrolimus	Placebo	
St Peter <i>et al.</i> , 2003 [21]	20	AST (IU/l)	AST (IU/l)	0.02
		day 1: 604	day 1: 1294	
		day 2: 683	day 2: 934	
Kristo <i>et al.</i> , 2011 [38]	26	ALT (IU/l)	ALT (IU/l)	0.88
		day 6: 79	day 6: 101	

ALT, alanine transaminase; AST, aspartate transaminase.

studies [22,39]. At this dosage no adverse effects related to the tacrolimus treatment have been reported. The 20 µg of tacrolimus dissolved in 1000 ml of Custodiol to form the rinse solution represents a minute fraction of the  $1.75 \times 10^3$  µg per day of tacrolimus administered intravenously to a 70 kg adult. If even 80% of the tacrolimus in the rinse solution reached the systemic circulation, the drug level would be below the detection limit of 3 ng/ml. Therefore, the rinse solution seems to have local effects in the liver graft, rather than contributing to systemic immunosuppression.

In summary, a tacrolimus rinse could represent a new strategy to reduce IRI and improve organ survival in EDC organs in liver transplantation. A reduction of organ damage in marginal grafts may allow the acceptance of more EDC organs, even in patients with high MELD scores, thereby safely expanding the donor pool in liver transplantation.

#### Abbreviations

ALT: alanine transaminase; AMG: German Pharmaceuticals Act (Arzneimittelgesetz); AST: aspartate transaminase; BfArM: Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte); CRO: contract research organization; CTS: Collaborative Transplant Study; DSO: German Organ Transplantation Foundation (Deutsche Stiftung Organtransplantation); EDC: extended donor criteria; GCP: Good Clinical Practice; HTK: histidine-tryptophan-ketoglutarate; IL: interleukin; IRI: ischemia reperfusion injury; ITBL: ischemic-type biliary lesions; LDH: lactate dehydrogenase; MELD: model for end-stage liver disease; NFAT: nuclear factor of activated T cells; NIS: non-interventional study; NO: nitric oxide; PVC: polyvinylchloride; ROS: reactive oxygen species; TAC: tacrolimus; TNF: tumor necrosis factor; TOP: tacrolimus organ perfusion.

#### Competing interests

The study is financed by a grant from Astellas Pharma GmbH, München, Germany.

#### Authors' contributions

SP performed experimental work, participated in the design of the study and wrote the manuscript. ME participated in the coordination of the study and helped to draft the manuscript. MH, SN, AP, PS, MS, FU and HW participated in performing the study (liver transplantation, organ rinse) and helped to draft the manuscript. KWJ participated in the study design and helped to draft the manuscript. DW participated in the study design, in coordination of the study and in statistical analysis. MA conceived the design of the study and helped to draft the manuscript. All authors read and approved the final manuscript.

#### Acknowledgement

We thank Dr Amanda Tufman for correcting and editing the English language and grammar of the manuscript.

#### Author details

<sup>1</sup>Department of Surgery, University of Munich Hospital, Campus Grosshadern, Ludwig-Maximilians-University, Marchioninistrasse 15, 81377 Munich, Germany. <sup>2</sup>Department of Transplantation Surgery, University Medical Center, Johannes Gutenberg University, Langenbeckstrasse 1, 55131 Mainz, Germany. <sup>3</sup>Department of General, Visceral and Transplantation Surgery, University Hospital Tübingen, Eberhard Karls University, Hoppe-Seyler-Strasse 3, 72076 Tübingen, Germany. <sup>4</sup>Department of General, Visceral and Transplantation Surgery, Charité Campus Virchow-Klinikum, Augustenburger Platz 1, 13353 Berlin, Germany. <sup>5</sup>Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Ruprecht-Karls-University, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany. <sup>6</sup>Department of Surgery, University Hospital Regensburg, University of Regensburg, Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany. <sup>7</sup>Department of

General and Visceral Surgery, Johann Wolfgang Goethe-University Frankfurt am Main, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany.

<sup>8</sup>Department of General and Visceral Surgery, University Hospital Münster, Westphalian Wilhelms-University, Waldeyerstrasse 1, 48149 Münster, Germany. <sup>9</sup>DABIO Gesellschaft für Auftragsforschung mbH, Altlaufstrasse 40, 85635 Höhenkirchen, Germany.

Received: 25 September 2012 Accepted: 13 February 2013

Published: 4 March 2013

#### References

1. Hasegawa T, Ito Y, Wijeweera J, Liu J, Malle E, Farhood A, McCuskey RS, Jaeschke H: **Reduced inflammatory response and increased microcirculatory disturbances during hepatic ischemia-reperfusion injury in steatotic livers of ob/ob mice.** *Am J Physiol Gastrointest Liver Physiol* 2007, **292**(5):G1385–G1395.
2. Teramoto K, Bowers JL, Kruskal JB, Clouse ME: **Hepatic microcirculatory changes after reperfusion in fatty and normal liver transplantation in the rat.** *Transplantation* 1993, **56**(5):1076–1082.
3. Nardo B, Caraceni P, Pasini P, Domenicali M, Catena F, Cavallari G, Santoni B, Maiolini E, Grattagliano I, Vendemiale G, Trevisani F, Roda A, Bernardi M, Cavallari A: **Increased generation of reactive oxygen species in isolated rat fatty liver during posts ischemic reoxygenation.** *Transplantation* 2001, **71**(12):1816–1820.
4. Angele MK, Rentsch M, Hartl WH, Wittmann B, Graeb C, Jauch KW, Loehe F: **Effect of graft steatosis on liver function and organ survival after liver transplantation.** *Am J Surg* 2008, **195**(2):214–220.
5. Mutimer DJ, Gunson B, Chen J, Berenguer J, Neuhaus P, Castaing D, Garcia-Valdecasas JC, Salizzoni M, Moreno GE, Mirza D: **Impact of donor age and year of transplantation on graft and patient survival following liver transplantation for hepatitis C virus.** *Transplantation* 2006, **81**(1):7–14.
6. Jaeschke H: **Molecular mechanisms of hepatic ischemia-reperfusion injury and preconditioning.** *Am J Physiol Gastrointest Liver Physiol* 2003, **284**(1):G15–G26.
7. Jaeschke H: **Role of reactive oxygen species in hepatic ischemia-reperfusion injury and preconditioning.** *Invest Surg* 2003, **16**(3):127–140.
8. Bilzer M, Gerbes AL: **Preservation injury of the liver: mechanisms and novel therapeutic strategies.** *J Hepatol* 2000, **32**(3):508–515.
9. Raina A, Horn ET, Benza RL: **The pathophysiology of endothelin in complications after solid organ transplantation: a potential novel therapeutic role for endothelin receptor antagonists.** *Transplantation* 2012, **94**(9):885–893.
10. Abu-Amara M, Yang SY, Seifalian A, Davidson B, Fuller B: **The nitric oxide pathway—evidence and mechanisms for protection against liver ischaemia reperfusion injury.** *Liver Int* 2012, **32**(4):531–543.
11. Sun CK, Zhang XY, Zimmermann A, Davis G, Wheatley AM: **Effect of ischemia-reperfusion injury on the microcirculation of the steatotic liver of the Zucker rat.** *Transplantation* 2001, **72**(10):1625–1631.
12. Ijaz S, Yang W, Winslet MC, Seifalian AM: **Impairment of hepatic microcirculation in fatty liver.** *Microcirculation* 2003, **10**(6):447–456.
13. Pratschke S, Loehe F, Graeb C, Jauch KW, Angele MK: **Usage of marginal organs for liver transplantation: a way around the critical organ shortage?** *Zentralbl Chir* 2009, **134**(2):107–112.
14. Pratschke S, Bilzer M, Grutzner U, Angele M, Tufman A, Jauch KW, Schauer RJ: **Tacrolimus preconditioning of rat liver allografts impacts glutathione homeostasis and early reperfusion injury.** *J Surg Res* 2012, **176**(1):309–316.
15. Sakr MF, Zetti GM, Farghali H, Hassanein TH, Gavalier JS, Starzl TE: **Protective effect of FK 506 against hepatic ischemia in rats.** *Transplant Proc* 1991, **23**(1 Pt 1):340–341.
16. Kawano K, Bowers JL, Clouse ME: **Protective effect of FK 506 on hepatic injury following cold ischemic preservation and transplantation: influence on hepatic microcirculation.** *Transplant Proc* 1995, **27**(1):362–363.
17. Kawano K, Bowers JL, Kim YI, Tatsuma T, Kitano S, Kobayashi M, Clouse ME: **FK506 reduces oxidative hepatic injury following cold ischemic preservation and transplantation.** *Transplant Proc* 1996, **28**(3):1902–1903.
18. Garcia-Criado FJ, Palma-Vargas JM, Valdunciel-Garcia JJ, Toledo AH, Misawa K, Gomez-Alonso A, Toledo-Pereyra LH: **Tacrolimus (FK506) down-regulates free radical tissue levels, serum cytokines, and neutrophil infiltration after severe liver ischemia.** *Transplantation* 1997, **64**(4):594–598.
19. Takeichi T, Uemoto S, Minamiguchi S, Takeyoshi I, Inomata Y, Tanaka K, Kobayashi E: **Effect of ONO-4057 and tacrolimus on ischemia-reperfusion injury of the liver.** *World J Gastroenterol* 2009, **15**(45):5712–5715.

20. Huser N, Doll D, Altomonte J, Werner M, Kriner M, Preissel A, Thorban S, Matevossian E: **Graft preconditioning with low-dose tacrolimus (FK506) and nitric oxide inhibitor aminoguanidine (AGH) reduces ischemia/reperfusion injury after liver transplantation in the rat.** *Arch Pharm Res* 2009, **32**(2):215–220.
21. Eurotransplant International Foundation: *Eurotransplant Manual*. Leiden: Eurotransplant International Foundation; 2009.
22. Peter S, Post DJ, Rodriguez-Davalos MI, Douglas DD, Moss AA, Mulligan DC: **Tacrolimus as a liver flush solution to ameliorate the effects of ischemia/reperfusion injury following liver transplantation.** *Liver Transpl* 2003, **9**(2):144–149.
23. Pratschke S, Angele MK, Grutzner U, Tufman A, Bilzer M, Loehe F, Jauch KW, Schauer RJ: **GSH attenuates organ injury and improves function after transplantation of fatty livers.** *Eur Surg Res* 2010, **45**(1):13–19.
24. Schauer RJ, Kalmuk S, Gerbes AL, Leiderer R, Meissner H, Schildberg FW, Messmer K, Bilzer M: **Intravenous administration of glutathione protects parenchymal and non-parenchymal liver cells against reperfusion injury following rat liver transplantation.** *World J Gastroenterol* 2004, **10**(6):864–870.
25. Burroughs AK, Sabin CA, Rolles K, Delvart V, Karam V, Buckels J, O'Grady JG, Castaing D, Klempnauer J, Jamieson N, Neuhaus P, Lerut J, de Ville de Goyet J, Pollard S, Salizzoni M, Rogiers X, Muhlbacher F, Garcia Valdecasas JC, Broelsch C, Jaeck D, Berenguer J, Gonzalez EM, Adam R, European Liver Transplant Association: **3-month and 12-month mortality after first liver transplant in adults in Europe: predictive models for outcome.** *Lancet* 2006, **367**(9506):225–232.
26. Adam R, Cailliez V, Majno P, Karam V, McMaster P, Caine RY, O'Grady J, Pichlmayr R, Neuhaus P, Otte JB, Hoeckerstedt K, Bismuth H: **Normalised intrinsic mortality risk in liver transplantation: European liver transplant registry study.** *Lancet* 2000, **356**(9230):621–627.
27. Banerji SS, Parsons JN, Tocci MJ: **The immunosuppressant FK-506 specifically inhibits mitogen-induced activation of the interleukin-2 promoter and the isolated enhancer elements NFIL-2A and NF-AT1.** *Mol Cell Biol* 1991, **11**(8):4074–4087.
28. Yoshimura N, Matsui S, Hamashima T, Oka T: **Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. I. Inhibition of expression of alloantigen-activated suppressor cells, as well as induction of alloreactivity.** *Transplantation* 1989, **47**(2):351–356.
29. Zwacka RM, Zhang Y, Halldorson J, Schlossberg H, Dudus L, Engelhardt JF: **CD4(+) T-lymphocytes mediate ischemia/reperfusion-induced inflammatory responses in mouse liver.** *J Clin Invest* 1997, **100**(2):279–289.
30. Khandoga A, Hanschen M, Kessler JS, Krombach F: **CD4+ T cells contribute to posts ischemic liver injury in mice by interacting with sinusoidal endothelium and platelets.** *Hepatology* 2006, **43**(2):306–315.
31. Shen X, Wang Y, Gao F, Ren F, Busuttill RW, Kupiec-Weglinski JW, Zhai Y: **CD4 T cells promote tissue inflammation via CD40 signaling without de novo activation in a murine model of liver ischemia/reperfusion injury.** *Hepatology* 2009, **50**(5):1537–1546.
32. Zhang Y, Ji H, Shen X, Cai J, Gao F, Koenig KM, Batikian CM, Busuttill RW, Kupiec-Weglinski JW: **Targeting TIM-1 on CD4 T cells depresses macrophage activation and overcomes ischemia-reperfusion injury in mouse orthotopic liver transplantation.** *Am J Transplant* 2012, **8**:10–6143.
33. Hanschen M, Zahler S, Krombach F, Khandoga A: **Reciprocal activation between CD4+ T cells and Kupffer cells during hepatic ischemia-reperfusion.** *Transplantation* 2008, **86**(5):710–718.
34. Jaeschke H, Farhood A: **Neutrophil and Kupffer cell-induced oxidant stress and ischemia-reperfusion injury in rat liver.** *Am J Physiol* 1991, **260**(3 Pt 1):G355–G362.
35. Yadav SS, Howell DN, Gao W, Steeber DA, Harland RC, Clavien PA: **L-selectin and ICAM-1 mediate reperfusion injury and neutrophil adhesion in the warm ischemic mouse liver.** *Am J Physiol* 1998, **275**(6 Pt 1):G1341–G1352.
36. Squadrito F, Altavilla D, Squadrito G, Saitta A, Deodato B, Arlotta M, Minutoli L, Quartarone C, Ferlito M, Caputi AP: **Tacrolimus limits polymorphonuclear leucocyte accumulation and protects against myocardial ischaemia-reperfusion injury.** *J Mol Cell Cardiol* 2000, **32**(3):429–440.
37. Garcia-Criado FJ, Lozano-Sanchez F, Fernandez-Regalado J, Valdunciel-Garcia JJ, Parreno-Manchado F, Silva-Benito I, Zambrano-Cuadrado Y, Gomez-Alonso A: **Possible tacrolimus action mechanisms in its protector effects on ischemia-reperfusion injury.** *Transplantation* 1998, **66**(7):942–943.
38. Tojimbata T, Bermudez LE, Egawa H, Hayashi M, So SK, Esquivel CO: **Cyclosporine and tacrolimus both suppress activation of Kupffer cells in vitro.** *Transplant Proc* 1996, **28**(3):1381–1382.
39. Kristo I, Wilflingseder J, Kainz A, Marschalek J, Wekerle T, Mühlbacher F, Oberbauer R, Bodingbauer M: **Effect of intraportal infusion of tacrolimus on ischaemic reperfusion injury in orthotopic liver transplantation: a randomized controlled trial.** *Transpl Int* 2011, **24**(9):912–919.
40. Soda Y, el-Assal ON, Yu L, Nagasue N: **Suppressed endothelin-1 production by FK506 and cyclosporin A in ischemia/reperfusion of rat small intestine.** *Surgery* 1999, **125**(1):23–32.
41. Gomez-Lechon MJ, Serrata A, Donato MT, Jimenez N, O'connor E, Castell JV, Mir J: **The immunosuppressant drug FK506 prevents Fas-induced apoptosis in human hepatocytes.** *Biochem Pharmacol* 2004, **68**(12):2427–2433.
42. Crenesse D, Laurens M, Heurteaux C, Cursio R, Saint-Paul MC, Schmid-Alliana A, Gugenheim J: **Rat liver ischemia-reperfusion-induced apoptosis and necrosis are decreased by FK506 pretreatment.** *Eur J Pharmacol* 2003, **473**(2–3):177–184.
43. Puhl G, Schaser KD, Pust D, Kohler K, Vollmar B, Menger MD, Neuhaus P, Settmacher U: **Initial hepatic microcirculation correlates with early graft function in human orthotopic liver transplantation.** *Liver Transpl* 2005, **11**(5):555–563.
44. Pratschke J, Weiss S, Neuhaus P, Pascher A: **Review of nonimmunological causes for deteriorated graft function and graft loss after transplantation.** *Transpl Int* 2008, **21**(6):512–522.

doi:10.1186/2047-1440-2-3

**Cite this article as:** Pratschke et al.: Protocol TOP-Study (tacrolimus organ perfusion): a prospective randomized multicenter trial to reduce ischemia reperfusion injury in transplantation of marginal liver grafts with an ex vivo tacrolimus perfusion. *Transplantation Research* 2013 **2**:3.

**Submit your next manuscript to BioMed Central and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
www.biomedcentral.com/submit

